Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vipul Kumar

Showing results (121-130 of 133) with videos related to

Pageof 14
Sort By:
Frontiers in Immunology|June 20, 2022
B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint BlockadeShubhra Singh, Jason Roszik, Neeraj Saini, et al.
Cureus|May 13, 2024
Evaluating the Efficacy, Safety, and Tolerability of Combination Therapy of Dapagliflozin and Linagliptin Over Dapagliflozin and Vildagliptin in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With MetforminMala Dharmalingam, Surendra Kumar Sharma, Ved Prakash, et al.
Bioorganic & Medicinal Chemistry Letters|February 18, 2011
Novel second generation analogs of eribulin. Part III: Blood-brain barrier permeability and in vivo activity in a brain tumor modelSridhar Narayan, Eric M Carlson, Hongsheng Cheng, et al.
Bioorganic & Medicinal Chemistry Letters|February 18, 2011
Novel second generation analogs of eribulin. Part II: Orally available and active against resistant tumors in vivoSridhar Narayan, Eric M Carlson, Hongsheng Cheng, et al.
Iscience|March 15, 2020
Loss of H3K36 Methyltransferase SETD2 Impairs V(D)J Recombination during Lymphoid DevelopmentS Haihua Chu, Jonathan R Chabon, Chloe N Matovina, et al.
Nature Communications|June 17, 2025
Bladder cancer variants share aggressive features including a CA125+ cell state and targetable TM4SF1 expressionHeiko Yang, Hanbing Song, Elizabeth Yip, et al.
Frontiers in Oncology|April 24, 2023
Somatic alterations of <i>TP53</i> and <i>MDM2</i> associated with response to enfortumab vedotin in patients with advanced urothelial cancerTanya Jindal, Xiaolin Zhu, Rohit Bose, et al.
ACS Medicinal Chemistry Letters|October 22, 2015
Discovery of Indazole Derivatives as a Novel Class of Bacterial Gyrase B InhibitorsJing Zhang, Qingyi Yang, Jan Antoinette C Romero, et al.
Clinical Genitourinary Cancer|June 14, 2023
Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab VedotinTanya Jindal, Li Zhang, Prianka Deshmukh, et al.
The Oncologist|June 22, 2024
HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gainsXiaolin Zhu, Emily Chan, Michelle L Turski, et al.
Pageof 14

Showing results (121-130 of 133) with videos related to

Sort By:
Pageof 14
Frontiers in Immunology|June 20, 2022
B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint BlockadeShubhra Singh, Jason Roszik, Neeraj Saini, et al.
Cureus|May 13, 2024
Evaluating the Efficacy, Safety, and Tolerability of Combination Therapy of Dapagliflozin and Linagliptin Over Dapagliflozin and Vildagliptin in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With MetforminMala Dharmalingam, Surendra Kumar Sharma, Ved Prakash, et al.
Bioorganic & Medicinal Chemistry Letters|February 18, 2011
Novel second generation analogs of eribulin. Part III: Blood-brain barrier permeability and in vivo activity in a brain tumor modelSridhar Narayan, Eric M Carlson, Hongsheng Cheng, et al.
Bioorganic & Medicinal Chemistry Letters|February 18, 2011
Novel second generation analogs of eribulin. Part II: Orally available and active against resistant tumors in vivoSridhar Narayan, Eric M Carlson, Hongsheng Cheng, et al.
Iscience|March 15, 2020
Loss of H3K36 Methyltransferase SETD2 Impairs V(D)J Recombination during Lymphoid DevelopmentS Haihua Chu, Jonathan R Chabon, Chloe N Matovina, et al.
Nature Communications|June 17, 2025
Bladder cancer variants share aggressive features including a CA125+ cell state and targetable TM4SF1 expressionHeiko Yang, Hanbing Song, Elizabeth Yip, et al.
Frontiers in Oncology|April 24, 2023
Somatic alterations of <i>TP53</i> and <i>MDM2</i> associated with response to enfortumab vedotin in patients with advanced urothelial cancerTanya Jindal, Xiaolin Zhu, Rohit Bose, et al.
ACS Medicinal Chemistry Letters|October 22, 2015
Discovery of Indazole Derivatives as a Novel Class of Bacterial Gyrase B InhibitorsJing Zhang, Qingyi Yang, Jan Antoinette C Romero, et al.
Clinical Genitourinary Cancer|June 14, 2023
Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab VedotinTanya Jindal, Li Zhang, Prianka Deshmukh, et al.
The Oncologist|June 22, 2024
HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gainsXiaolin Zhu, Emily Chan, Michelle L Turski, et al.
Pageof 14